{
  "@context": "aku-v2",
  "@type": "concept",
  "@id": "wsmg:health-sciences:medicine:surgery:vascular:pathology:vasculitis:vasc-017",
  "metadata": {
    "version": "2.1.0",
    "created": "2026-01-08T22:00:00.000Z",
    "modified": "2026-01-08T22:00:00.000Z",
    "contributors": ["copilot-agent", "vascular-surgery-sme"],
    "confidence": 0.91,
    "status": "pending-quality-check",
    "language": "en",
    "licenses": ["CC-BY-4.0"]
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/pathology/vasculitis",
    "subdomain": "large-vessel-vasculitis",
    "type": "definition",
    "difficulty": "advanced",
    "importance": "critical",
    "isNativeDomain": true,
    "board_yield": "HIGH"
  },
  "content": {
    "title": "Takayasu Arteritis",
    "summary": "Takayasu arteritis is a large-vessel vasculitis primarily affecting the aorta and its major branches. It predominantly occurs in young women and can cause stenosis, occlusion, or aneurysm formation, leading to limb claudication, renovascular hypertension, or cerebrovascular symptoms.",
    "definition": "A chronic granulomatous vasculitis of large arteries, primarily the aorta and its major branches, characterized by inflammatory cell infiltration and intimal hyperplasia leading to stenosis, occlusion, or aneurysm formation",
    "epidemiology": {
      "demographics": {
        "age_onset": "Typically 10-40 years",
        "sex": "Female predominance (80-90%)",
        "ethnicity": "More common in Asian populations"
      },
      "incidence": "1-3 per million in North America; higher in Asia"
    },
    "pathophysiology": {
      "inflammation": "Granulomatous inflammation of vessel wall",
      "target": "Media and adventitia of aorta and branches",
      "progression": {
        "early": "Inflammatory (active) phase - may be asymptomatic",
        "late": "Fibrotic (pulseless) phase - stenosis/occlusion predominates"
      },
      "consequences": ["Stenosis", "Occlusion", "Aneurysm", "Dissection (rare)"]
    },
    "clinical_presentation": {
      "systemic_symptoms": {
        "early_phase": ["Fever", "Malaise", "Weight loss", "Arthralgias", "Night sweats"],
        "frequency": "Often absent or resolved by diagnosis"
      },
      "vascular_symptoms": {
        "upper_extremity": "Arm claudication, pulse deficits (pulseless disease)",
        "cerebrovascular": "TIA, stroke, visual disturbances, dizziness",
        "hypertension": "Renovascular hypertension from renal artery stenosis",
        "cardiac": "Aortic regurgitation, coronary involvement, CHF",
        "abdominal": "Mesenteric ischemia (rare)"
      },
      "physical_findings": {
        "pulse_deficits": "Absent or diminished pulses",
        "bruits": "Over carotid, subclavian, abdominal aorta",
        "blood_pressure": "Discrepancy between arms; often difficult to measure"
      }
    },
    "classification_types": {
      "Numano_classification": {
        "type_I": "Branches of aortic arch only",
        "type_IIa": "Ascending aorta, arch, and branches",
        "type_IIb": "Type IIa plus thoracic descending aorta",
        "type_III": "Thoracic descending, abdominal aorta, renal arteries",
        "type_IV": "Abdominal aorta and/or renal arteries only",
        "type_V": "Combined features of IIb and IV (entire aorta)"
      }
    },
    "diagnosis": {
      "clinical_criteria": {
        "ACR_criteria": [
          "Age of onset <40 years",
          "Claudication of an extremity",
          "Decreased brachial artery pulse",
          "BP difference >10mmHg between arms",
          "Bruit over subclavian or aorta",
          "Arteriographic abnormality"
        ],
        "diagnosis": "3 or more criteria (sensitivity 90.5%)"
      },
      "laboratory": {
        "ESR_CRP": "Elevated in active phase, may be normal in burnt-out disease",
        "limitations": "Poor correlation with disease activity"
      },
      "imaging": {
        "CTA_MRA": {
          "role": "First-line for diagnosis and surveillance",
          "findings": ["Vessel wall thickening", "Stenosis", "Occlusion", "Aneurysm"]
        },
        "PET_CT": {
          "role": "Assess disease activity",
          "findings": "FDG uptake in vessel wall indicates active inflammation"
        },
        "conventional_angiography": {
          "role": "Gold standard for detail; rarely needed for diagnosis"
        }
      }
    },
    "treatment": {
      "medical": {
        "glucocorticoids": {
          "role": "First-line for active disease",
          "dose": "Prednisone 0.5-1 mg/kg/day",
          "taper": "Gradual over months"
        },
        "immunosuppressives": {
          "indication": "Steroid-sparing, refractory disease",
          "options": ["Methotrexate", "Azathioprine", "Mycophenolate"]
        },
        "biologics": {
          "tocilizumab": "IL-6 inhibitor; FDA approved for Takayasu",
          "TNF_inhibitors": "Used in refractory cases"
        }
      },
      "revascularization": {
        "indications": [
          "Symptomatic stenosis (claudication, ischemia)",
          "Critical stenosis (cerebrovascular, renal)",
          "Aneurysm at risk for rupture"
        ],
        "timing": "Best during quiescent phase (disease control first)",
        "surgical_options": {
          "bypass": "Preferred for long stenoses",
          "endarterectomy": "Limited role; friable tissue"
        },
        "endovascular": {
          "balloon_angioplasty": "May be considered for focal stenoses",
          "stenting": "Higher restenosis rate than other vascular diseases"
        },
        "outcomes": "Higher restenosis in Takayasu; disease control critical"
      }
    },
    "prognosis": {
      "survival": "Generally good with treatment (80-90% at 10 years)",
      "morbidity": "Significant from vascular complications",
      "monitoring": "Long-term follow-up required; relapses common"
    }
  },
  "skos": {
    "prefLabel": {"@language": "en", "@value": "Takayasu Arteritis"},
    "altLabel": [
      {"@language": "en", "@value": "Pulseless disease"},
      {"@language": "en", "@value": "Takayasu's arteritis"},
      {"@language": "en", "@value": "Aortic arch syndrome"}
    ],
    "definition": {"@language": "en", "@value": "Large-vessel granulomatous vasculitis affecting the aorta and major branches, primarily in young women"},
    "notation": "vasc-017"
  },
  "relationships": {
    "skos:broader": [{"@id": "wsmg:health-sciences:medicine:surgery:vascular:pathology:vasculitis", "skos:prefLabel": "Vasculitis"}],
    "skos:related": [
      {"@id": "wsmg:health-sciences:medicine:surgery:vascular:pathology:vasculitis:gca", "skos:prefLabel": "Giant Cell Arteritis"},
      {"@id": "wsmg:health-sciences:medicine:rheumatology:vasculitis", "skos:prefLabel": "Systemic Vasculitis"}
    ]
  },
  "medicalCode": [
    {
      "@type": "MedicalCode",
      "codingSystem": "ICD-10-CM",
      "codeValue": "M31.4",
      "description": "Aortic arch syndrome [Takayasu]"
    },
    {
      "@type": "MedicalCode",
      "codingSystem": "SNOMED-CT",
      "codeValue": "36713002",
      "uri": "http://snomed.info/id/36713002",
      "description": "Takayasu disease"
    }
  ],
  "pedagogical": {
    "learning_objectives": [
      "Describe epidemiology and pathophysiology of Takayasu arteritis",
      "Apply ACR diagnostic criteria",
      "Classify disease extent using Numano classification",
      "Outline medical treatment including biologics",
      "Identify timing and approach for revascularization"
    ],
    "clinical_pearls": [
      "Young woman with pulse deficits and BP discrepancy = think Takayasu",
      "ESR/CRP may be normal in burnt-out disease",
      "PET-CT best for assessing disease activity",
      "Revascularize during quiescent phase for best outcomes",
      "Tocilizumab (IL-6 inhibitor) now FDA approved for Takayasu"
    ],
    "estimated_time": "30min",
    "target_audience": ["vascular_surgery_residents", "rheumatology", "cardiology"]
  }
}
